[Skip to Navigation]
Comment & Response
July 2017

Potential of Oncocardiology

Author Affiliations
  • 1Unit of Heart Failure and Valvular Heart Diseases, Department of Cardiology, Mediterranean University Cardio-Oncology Center, Aix-Marseille Univ, Hôpital NORD, Assistance Publique–Hôpitaux de Marseille, Marseille, France
  • 2Oncosafety Network of the Early Phases Cancer Trials Center, Aix-Marseille Univ, Assistance Publique–Hôpitaux de Marseille, Marseille, France
  • 3Groupe Méditerranéen de Cardio-Oncologie, Marseille, France
  • 4Mediterranean Association for Research and Studies in Cardiology, Marseille, France
  • 5Technological Advances for Genomics and Clinics, Aix-Marseille Univ, UMR/INSERM 1090, Marseille, France
JAMA Cardiol. 2017;2(7):817-818. doi:10.1001/jamacardio.2017.0119

To the Editor We read the recent review by Yeh and Chang1 with interest and congratulate them for reinforcing the role of cardio-oncology (oncocardiology), an emergent discipline in the cardiology field. This article is timely in the context of the proliferation of new cancer therapies and the increase in the number of cancer survivors. Cardiovascular care for cancer patients has become challenging because they live longer and are at greater risk of cardiovascular events. Yeh and Chang1 pointed out the well-known toxic effects of anthracyclines, but they also underlined the cardiovascular toxicity resulting from the anti-HER2 and anti-VEGF antibodies, inhibitors of tyrosine kinases and of other intracellular signals. This description is very important because it aims at educating the cardiology community about the growing issue of cardiotoxicity in cancer patients.1

Add or change institution